PD-L2 overexpression
|
Prostate Cancer
|
PD-L2 overexpression
|
Prostate Cancer
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L2 overexpression
|
Melanoma
|
PD-L2 overexpression
|
Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PD-L2 overexpression
|
Melanoma
|
PD-L2 overexpression
|
Melanoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
PD-L2 overexpression
|
Melanoma
|
PD-L2 overexpression
|
Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L2 overexpression
|
SCCHN
|
PD-L2 overexpression
|
SCCHN
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
PD-L2 overexpression
|
Triple Negative Breast Cancer
|
PD-L2 overexpression
|
Triple Negative Breast Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L2 overexpression
|
Triple Negative Breast Cancer
|
PD-L2 overexpression
|
Triple Negative Breast Cancer
|
capecitabine Sensitive: C3 – Early Trials
|
capecitabine Sensitive: C3 – Early Trials
|
PD-L2 overexpression
|
AML
|
PD-L2 overexpression
|
AML
|
avelumab Resistant: D – Preclinical
|
avelumab Resistant: D – Preclinical
|
PD-L2 overexpression
|
Colorectal Adenocarcinoma
|
PD-L2 overexpression
|
Colorectal Adenocarcinoma
|
PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical
|
PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical
|
PD-L2 overexpression
|
Endometrial Cancer
|
PD-L2 overexpression
|
Endometrial Cancer
|
paclitaxel Sensitive: D – Preclinical
|
paclitaxel Sensitive: D – Preclinical
|